Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Status Recruiting

Clinical Trial Summary

The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radiolabeled somatostatin analog therapy, also referred to as peptide receptor radiotherapy (PRRT), can be a potential alternative in the future. At this time, radiolabeled somatostatin analogs have not been tested in patients with poorly differentiated neuroendocrine carcinomas, and their efficacy in this disease is not well known Understanding the extent and degree of somatostatin receptor expression is important in order to evaluate the potential of radiolabeled somatostatin analog therapy for treatment of poorly differentiated neuroendocrine carcinomas.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04069299
Study type	Observational
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Recruiting
Phase
Start date	September 25, 2019
Completion date	May 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01642251` - Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT04464122` - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Recruiting	`NCT04325425` - Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary	Phase 2
Completed	`NCT03834701` - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms	N/A
Recruiting	`NCT03279614` - Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT05978284` - Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05076786` - Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma	Phase 2
Completed	`NCT00388063` - Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma	Phase 2
Withdrawn	`NCT03901378` - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT02970786` - Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans	Phase 1
Completed	`NCT00663429` - Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT05113355` - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm	Phase 2
Completed	`NCT03278405` - Avelumab in G3 NEC	Phase 1/Phase 2
Active, not recruiting	`NCT03837977` - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma	Phase 2
Not yet recruiting	`NCT06333314` - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI	Phase 2
Active, not recruiting	`NCT02687958` - Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin	Phase 2
Completed	`NCT01121939` - Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers	Phase 2
Recruiting	`NCT03168607` - Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma	Phase 2
Enrolling by invitation	`NCT05396118` - Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients	Phase 2
Completed	`NCT03079440` - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors	Phase 2